LPGO — Lipigon Pharmaceuticals AB Cashflow Statement
0.000.00%
- SEK32.87m
- SEK8.87m
- SEK32.81m
Annual cashflow statement for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.93 | -7.82 | -41.2 | -37.7 | -12.4 |
Depreciation | |||||
Non-Cash Items | — | — | -0.243 | -0.023 | 0.093 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.625 | -0.801 | 6.11 | 0.274 | -2.05 |
Change in Accounts Receivable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -11.1 | -17.3 | -70.6 | -74.9 | -28.6 |
Capital Expenditures | — | — | -0.119 | 0 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -1.5 | 1.25 | — | — | — |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -3 | 2.5 | -0.238 | 0 | — |
Financing Cash Flow Items | — | -0.769 | -5.22 | -3.99 | -6.56 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 16 | 37.8 | 102 | 37.2 | 73.4 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.937 | 11.5 | 15.9 | -18.8 | 22.3 |